Abstract: Systems and methods are provided for predicting treatment-regimen-related outcomes (e.g., risks of regimen-related toxicities). A predictive model is determined for predicting treatment-regimen-related outcomes and applied to a plurality of datasets. An ensemble algorithm is applied on result data generated from the application of the predictive model. Treatment-regimen-related outcomes are predicted using the predictive model. A combination of machine learning prediction and patient preference assessment is provided for enabling informed consent and precise treatment decisions.

Abstract: Systems and methods are provided for predicting treatment-regimen-related outcomes (e.g., risks of regimen-related toxicities). A predictive model is determined for predicting treatment-regimen-related outcomes and applied to a plurality of datasets. An ensemble algorithm is applied on result data generated from the application of the predictive model. Treatment-regimen-related outcomes are predicted using the predictive model. A combination of machine learning prediction and patient preference assessment is provided for enabling informed consent and precise treatment decisions.

Abstract: A concentration device (10) includes a sample collector (3) and a main chamber (1). In some embodiments, the concentration device includes a solution chamber (4) that holds a concentrating solution that is released from the solution chamber (4) and mixes with the sample obtained by the sample collector (3). In some embodiments, the concentration device includes a microfluidic channel through which sample can move, and a pressure pump may be used to move the sample through the microfluidic channel. The concentration device can be used in performing a method of obtaining a Raman spectrum characteristic of a microbe. The concentration device can be used in performing a method of detecting and identifying a microbe in a sample.

Abstract: Systems and methods are provided for predicting treatment-regimen-related outcomes (e.g., risks of regimen-related toxicities). A predictive model is determined for predicting treatment-regimen-related outcomes and applied to a plurality of datasets. An ensemble algorithm is applied on result data generated from the application of the predictive model. Treatment-regimen-related outcomes are predicted using the predictive model. A combination of machine learning prediction and patient preference assessment is provided for enabling informed consent and precise treatment decisions.

Abstract: Systems and methods are provided for predicting treatment-regimen-related outcomes (e.g., risks of regimen-related toxicities). A predictive model is determined for predicting treatment-regimen-related outcomes and applied to a plurality of datasets. An ensemble algorithm is applied on result data generated from the application of the predictive model. Treatment-regimen-related outcomes are predicted using the predictive model. A combination of machine learning prediction and patient preference assessment is provided for enabling informed consent and precise treatment decisions.

Abstract: An animal model has been developed based the understanding that a central mechanism in patients with CTRF is that chemotherapy and/or radiation initiates canonical pathways leading to the development of disrupted sleep architecture, resulting in disruption of REM sleep and fatigue and cognitive dysfunction. Drugs that restore the activity patterns and levels towards normal and/or decrease the pro-inflammatory cytokines associated with the disrupted sleep, should be effective in alleviating one or more symptoms of CTRF. Pentoxifylline was demonstrated to improve activity levels in animals treated with etoposide.

Abstract: Disclosed are methods for treating various cancers. Methods encompass the administration of a first drug such as AP23573, temsirolimus or everolimus in combination with a second drug selected from Remicade, Humira, Enbrel, Raptiva, Abatacept, Actermra, Cimzia or anakinra. The methods are aimed at providing a desirable therapeutic window while maintaining prior, if not higher, dose levels of the first drug.

Abstract: Disclosed are methods for treating various cancers. Methods encompass the administration of an mTOR inhibitor in combination with a second drug selected from an ImiD, a PDE4 inhibitor, a p38 MAP kinase inhibitor, a xanthine anticytokine, a dual TACE/MMP inhibitor and a proteasome inhibitor. The methods are aimed at providing a desirable therapeutic window while maintaining prior, if not higher, dose levels of the mTOR inhibitor.

Abstract: Overall and constituent oral mucositis assessment scale scores are generated by the use of a probe to obtain moisture measurements at a particular site. A control collects data samples. A converter produces a value for the oral mucositis assessment scale (OMAS) in response to the collected data (DPM) in accordance with a correlation defined by: OMAS = DPM - DPM o K ? ( I ) .

Abstract: The invention features a method for the treatment or prevention of mucositis in an individual undergoing or preparing to undergo cancer treatment. The method includes administering a therapeutically effective amount of an inhibitor of NF-?B to an individual undergoing or preparing to undergo a treatment for cancer. In certain embodiments, the inhibitor is a compound having the formula: where R1 and R4 are OH, and R2 and R3 are independently OH or H, provided that when R1 and R2 are both OH, R1 and R2 cannot be disposed ortho to one another, and when R3 and R4 are both OH, R3 and R4 cannot be disposed ortho to one another. The compounds of formula I may be cis or trans.

Abstract: A method of reducing or inhibiting mucositis in a patient, which includes administering an inflammatory cytokine inhibitor or a mast cell inhibitor, or a combination thereof, is disclosed.

Abstract: Intervention for oral mucosal injury secondary to chemotherapy or radiation based on the inhibition in the synthesis of ceramide, blockage of its activity, or its digestion.

Abstract: The invention features a method for the treatment or prevention of mucositis in an individual undergoing or preparing to undergo cancer treatment. The method includes administering a therapeutically effective amount of an inhibitor of NF-&kgr;B to an individual undergoing or preparing to undergo a treatment for cancer.

Abstract: A method of reducing or inhibiting mucositis in a patient, which includes administering an inflammatory cytokine inhibitor or a mast cell inhibitor, or a combination thereof, is disclosed

Abstract: A method of reducing or inhibiting mucositis in a patient, which includes administering an inflammatory cytokine inhibitor or a mast cell inhibitor, or a combination thereof, is disclosed.

Abstract: The invention provides methods for treating inflammatory oral diseases, involving administration of combinations of inhibitors of TNF-&agr; and immunosuppressive agents.

Abstract: Intervention for oral mucosal injury secondary to chemotherapy or radiation based on the inhibition in the synthesis of ceramide, blockage of its activity, or its digestion.

Abstract: Intervention for oral mucosal injury secondary to chemotherapy or radiation based on the inhibition in the synthesis of ceramide, blockage of its activity, or its digestion.

Abstract: A method of reducing or inhibiting mucositis in a patient, which includes administering an inflammatory cytokine inhibitor or a mast cell inhibitor, or a combination thereof, is disclosed